Free Trial
→ Watch This Robotics Demo Before July 23rd (From Brownstone Research) (Ad)
NASDAQ:PRFX

PainReform 8/15/2024 Earnings Report

PainReform logo
$1.86 -0.11 (-5.58%)
Closing price 06/13/2025 03:58 PM Eastern
Extended Trading
$1.87 +0.01 (+0.54%)
As of 06/13/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

PainReform EPS Results

Actual EPS
-$1.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PainReform Announcement Details

Quarter
Date
8/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

PainReform's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

PainReform Earnings Headlines

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
May 27, 2025 | prnewswire.com
PainReform Ltd.
May 12, 2025 | barrons.com
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
June 15, 2025 | Brownstone Research (Ad)
PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania’s Largest Solar Projects
May 7, 2025 | finance.yahoo.com
PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects
May 7, 2025 | globenewswire.com
PainReform Regains Nasdaq Compliance as of April 16, 2025
April 17, 2025 | tipranks.com
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX), a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

View PainReform Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles